Ajanta Pharma Ltd

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a pharmaceutical company headquartered in Mumbai, India. It has a strong presence in the Branded Generic business in India and Emerging markets, and the Generic business in the USA. In India, the company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology, and Pain management. Recently, Ajanta also entered two new promising therapies of Nephrology and Gynaecology. Its brands hold leadership positions in the sub-therapeutic areas they are present in. In Emerging Markets, the company has a presence in Africa, South East Asia, West Asia, and CIS across broader therapeutic segments such as antimalarial, gastro, antibiotics, cardiology, dermatology, and pain management. As of March 30, 2026, Ajanta has 49 ANDA approvals, of which 49 are commercialized. It is awaiting US FDA approval for 19 ANDAs. The company plans to file 8-12 ANDAs every year. The company has state-of-the-art research facilities for formulation and API development located in Mumbai, India. Its R&D capabilities are evident from the number of first-to-market products launched by the company, providing patients with much-needed compliance and convenience. A dedicated and focused team of over 850 scientists work in R&D, which is growing continuously. Ajanta has 6 formulation manufacturing facilities located in India. Besides that, it also has an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facilities at Paithan (Maharashtra, India) and Dahej (Gujarat, India) have been approved by the US FDA. Ajanta continuously invests in enhancing its existing manufacturing facilities to meet current cGMP requirements and also constructs new facilities to meet the company’s growth requirements.